“Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials” (2024) Journal of Kidney Cancer, 11(3), pp. 51–58. doi:10.15586/jkcvhl.v11i3.352.